Onestopmesothelioma!!
  • General Information 1
    • Asbestos Survey Video
    • Asbestos Support in Wales
    • Help at Hasag
    • Take a Break Page 1 >
      • IATP mavis Award
    • British Uralite
    • A Womans Page
    • Comand Report
    • Royal Marsden Magazine
    • Whitstable Gazette
    • Oncology Forum Program
  • General Info 2
    • Asbestos video Awareness
    • The man Behind Mavis:-
    • Asbestos in Ships
    • Rays Blog
    • HSE at Work
    • Mavis Blog
  • Our Books
    • More Book Info.
  • Inforative Information
    • Asbestos Justice
    • Clinical Trials >
      • Maps of Trial centres
      • MK3475
      • Adams Trial
      • The Warm Chemo Trial
      • Frontiers in Oncology
      • Blocking The Pathway
      • Trials .Gov
      • A Meso Postmortem
      • Studies Good & Bad
      • Meso Report Study
      • Genes Linked to meso
      • Surving Mesothelioma.
    • Difuse Meso Payments
    • Before you Fly!
    • Help on Compensation >
      • Legal Compensation
    • Research Group
    • Treatment Centres
  • Interesting Information.
    • Is Meso Hereditary
    • Why Dont we all get Cancer
    • Armley UK Deadliest Town
    • A Meso Statement.
    • Myths on Mesothelioma.
    • Genes Linked to Meso Cancer
    • NHS Choices.
    • Your CT Scan >
      • More on CT/Pet Scans
    • Sex Is Good for You
    • Saatchi Bill >
      • Saatchi Bill 1
      • Saatchi Bill 2
      • mavis and The Saatchi Bill.
      • The Bill
  • Dust to Dust

Trials at .Gov

  •                                                        Full Details HERE:

A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles"

Search for studies:
  • Advanced Search
  • Help
  • Studies by Topic
  • Glossary
  • Find Studies »
  • About Clinical Studies »
  • Submit Studies »
  • Resources »
  • About This Site »
Text Size
  • Home
  • Find Studies
  • Study Record Detail
Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors This study is currently recruiting participants. Verified October 2013 by GlaxoSmithKline Sponsor: GlaxoSmithKline Information provided by (Responsible Party): GlaxoSmithKline ClinicalTrials.gov Identifier: NCT01138033 First received: June 3, 2010 Last updated: January 16, 2014 Last verified: October 2013 History of Changes
  • Full Text View
  • Tabular View
  • No Study Results Posted
  • Disclaimer
  • How to Read a Study Record
  Purpose This study is a Phase I dose escalation study in subjects with solid tumors. Part 1 will identify the maximum tolerated dose (MTD) using a dose-escalation procedure. Following identification of the MTD, enrollment into Parts 2, 3, 4 and 5 may be concurrent. Part 2 will explore further the safety, PK, tolerability, and anti-tumor activity of GSK2256098 in subjects with tumors known to overexpress focal adhesion kinase (FAK). Part 3 will characterize the range of biologically effective doses by assessing pharmacodynamic (PD) markers in hair, skin and tumor tissue at doses that will not go lower than 80 mg or above the MTD dose levels tested during the Phase 1 dose escalation. Part 4 will explore further the safety, PK, tolerability and anti-tumor activity of GSK2256098 in subjects with relapsed glioblastoma multiforme (GBM). The primary objective of this study is to determine the safety, tolerability, and MTD of GSK2256098. Secondary objectives are to characterize the pharmacokinetics (PK) of GSK2256098; to identify a range of biologically active doses; to explore the anti-tumor activity of GSK2256098, and to explore relationships between GSK2256098 PK, PD and clinical endpoints. Part 5 will investigate the time course, the extent of an apparent change in the PK of GSK2256098 following repeated dosing, and screen for potential CYP3A induction as a possible mechanism of reduced systemic exposure of GSK2256098 at Day 15 and later time points. The primary objective of this study is to determine the safety, tolerability, and MTD of GSK2256098.
Powered by Create your own unique website with customizable templates.